FTISADTSK
This stable signature peptide, FTISADTSK, is an endogenous fragment derived from Trastuzumab. It is designed for accurate quantification via selected reaction monitoring (SRM) in proteomics research. This tool is applicable for both in vitro and in vivo studies focusing on antibody pharmacokinetics and biomarker analysis.
Product Specifications
Field of Research
Metabolism Research
Molecular Weight
969.06
Storage Conditions
-20°C
Notes
For research use only.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog